Neurovalens
Belfast, Northern Ireland, United Kingdom · Biotechnology, Health Care, Manufacturing
Neurovalens is a healthtech company based in Belfast, specializing in combining neuroscience and technology to tackle global health challenges. It has developed medical devices designed to deliver noninvasive electrical stimulation to key areas of the brain and nervous system without the need for surgically implanted electrodes.
Key facts
- Headquarters
- Belfast, Northern Ireland, United Kingdom
- Employees
- 30
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Private
- Website
- neurovalens.com
- Company page
Recent activity at Neurovalens
- : Neurovalens raises £6M for neurostimulation devices. The funding will support the development of their innovative healthcare technologies.
- : Neurovalens Launches Modius Sleep, an FDA-Cleared Non-Invasive Device Designed to Treat Chronic Insomnia
- : Neurovalens Appoints Kate Willis as Vice President of Commercialization
- : Neurovalens raises £2.1M in funding and gains FDA approval for anxiety treatment wearable device
Neurovalens funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2025 | Funding Round | $6.0M |
| Apr 2024 | Seed | $2.1M |
Leadership
- Kate Willis, Vice President
- Iain Hendrick, Chief Project Officer
- Jason McKeown, Chief Executive Officer
Verified email and direct lines for Neurovalens’s decision-makers are on Fundz. See plans
Neurovalens in the news
- Neurovalens earns FDA nod for neuromod for PTSD - massdevice.com (May 26, 2026)
- FDA Clears Neurovalens’ Modius Sleep Device for Insomnia - NeurologyLive (Nov 06, 2023)
- FDA Grants De Novo Approval to Modius Spero, Neuromodulation Device for PTSD - Psychiatric Times (May 26, 2026)
- FDA clears Neurovalens' neurostim headset to treat chronic insomnia - Fierce Biotech (Nov 06, 2023)
- AASM congratulates Sleep Medicine Disruptors Innovation Award winners - American Academy of Sleep Medicine | AASM (Nov 17, 2025)
- Neurotech startup Neurovalens gets FDA clearance for noninvasive anxiety treatment - TechCrunch (Apr 08, 2024)
- Neurovalens earns European, UK approval for non-invasive neuromod - massdevice.com (Mar 24, 2026)
- Neurovalens Appoints Kate Willis as Vice President of Commercialization - PR Web (Jun 05, 2024)
Companies similar to Neurovalens
- Endo Tools Therapeutics · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Lazurite · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- SpineGuard® · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Tenon Medical · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- NVENTRIC · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
About Neurovalens: questions and answers
What does Neurovalens do?
Neurovalens is a healthtech company based in Belfast, specializing in combining neuroscience and technology to tackle global health challenges. It has developed medical devices designed to deliver noninvasive electrical stimulation to key areas of the brain and nervous system without the need for surgically implanted electrodes.
Where is Neurovalens headquartered?
Neurovalens is headquartered in Belfast, Northern Ireland, United Kingdom.
How many employees does Neurovalens have?
Neurovalens has about 30 employees.
Has Neurovalens raised funding?
Yes. Fundz has recorded 2 funding events for Neurovalens. The most recent, Funding Round of $6.0M, was in Aug 2025.
Who leads Neurovalens?
Kate Willis is a Vice President at Neurovalens.
What is the latest news on Neurovalens?
On Aug 22, 2025, Neurovalens raises £6M for neurostimulation devices. The funding will support the development of their innovative healthcare technologies.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy